oncoFISH™ Bladder: Ikonisys’ Automated Bladder Cancer Test, USFDA-Cleared for Marketing
Ikonisys Inc. is a developer of automated cell-based diagnostic products. The diagnostic products of Ikonisys are an automation of a standard but time-consuming laboratory technique: fluorescence in situ hybridization (FISH), which identifies chromosome aberrations associated with various diseases.
Recently, Ikonisys Inc.’s oncoFISH™ bladder has been cleared by the USFDA for marketing in the United States.
oncoFISH™ bladder detects aberrations for chromosomes 3, 7, 9, and 17 in cells found in urine sediment that help in the initial diagnosis of bladder cancer in patients with hematuria (blood in the urine) and the subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer.
Together with the company’s novel Ikoniscope® robotic digital microscopy platform, oncoFISH™ bladder enables automated testing of cells found in urine specimens to aid in the detection of bladder cancer.
According to Petros Tsipouras, M.D., Chairman and Chief Executive Officer of Ikonisys:
“oncoFISH bladder is expected to significantly reduce the time required to process test results while improving the accuracy of bladder cancer diagnosis, and we are prepared for its immediate launch.
We believe the Ikoniscope and associated oncoFISH and fastFISH automated diagnostic applications are an economical and dependable solution to subjective sample analysis, protracted turnaround times for test results, and the acute laboratory shortage of trained technical personnel.”
Read the full press release.
Tags: bladder-cancer, bladder-cancer-test, Ikonisys, oncoFISH-BladderRelated Stories
POSTED IN: on bladder cancer, on cancer diagnostics
0 opinions for oncoFISH™ Bladder: Ikonisys’ Automated Bladder Cancer Test, USFDA-Cleared for Marketing
No one has left a comment yet. You know what this means, right? You could be first!
Have an opinion? Leave a comment: